Midomafetamine
- Generic Name
- Midomafetamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
- Associated Conditions
- -
- Associated Therapies
- -
John Krystal, MD: Exploring the Future of Ketamine and Psychedelic Treatment
John Krystal, MD discusses the potential of ketamine and other psychedelics in treating psychiatric disorders, highlighting the antidepressant effects of ketamine and the development of drug combinations at Freedom Biosciences to extend ketamine's efficacy. The FDA's recent decision on MDMA-assisted therapy for PTSD has spurred further research into psychedelics for conditions like major depression, PTSD, migraine, and substance use disorders.
Ecstasy Faces Stumbling Blocks To FDA Approval
FDA rejection of Lykos Therapeutics' MDMA application for PTSD treatment led to layoffs and CEO change, opening opportunities for PharmAla Biotech to supply MDMA for clinical trials. PharmAla focuses on non-U.S. markets and plans physician education for MDMA use in PTSD and other mental health conditions.
Stocks to Watch in the Battle Against Fentanyl and Dangerous Drugs
Greenlane Holdings, Inc. (NASDAQ: GNLN) plans to launch fentanyl, xylazine, and drink spike detection test strips under the Safety Strips brand, available from September 25th. The global opioid overdose treatment market is expected to reach $1.54 billion in 2024, with a projected CAGR of 7.2% through 2034.
Congressional Caucus Seeks Input On Psychedelic Therapy To Inform Development Of ...
Congressional lawmakers seek public input on creating a regulatory framework for psychedelic therapies, emphasizing the need for inclusive, responsible, and ethical use, and considering the cultural practices of indigenous communities.
Pharma Pulse: 9/18/24: How Drug Shortages Affect Pharmacovigilance, Long Strange Trip ...
Drug shortages, including critical antibiotics, fever medications, and cancer treatments, highlight global supply chain issues and the need for improved health policies. The FDA rejected MDMA for PTSD treatment, with psilocybin next for treatment-resistant depression. Companion apps tested for alleviating loneliness. Advanced Clinical named one of Crain's Best Places to Work in Chicago 2024. Luke Forsthoefel's thought leadership article published in Pharmaceutical Executive magazine.
Safe Supply Streaming Portfolio Company Safety Strips Launches Affordable and Reliable Drug Detection Strips
Safe Supply Streaming's portfolio company, Safety Strips, launches affordable drug detection strips to combat fentanyl, xylazine, and drink spiking, in response to new California legislation. The strips will be available via Greenlane Holdings' distribution channels starting September 25, 2024.
Safe Supply Streaming Portfolio Company Safety Strips Launches Affordable and Reliable ...
Safe Supply Streaming Co Ltd. launches Safety Strips Inc. to combat fentanyl, xylazine, and drink spiking, aligning with California's AB 1013 legislation. Products available from September 25, 2024, through Greenlane Holdings' distribution network.
Lykos Could See Five-Year Delay In Possible FDA Approval Of MDMA
FDA rejection of Lykos Therapeutics’ midomafetamine (MDMA) for PTSD could delay U.S. patient access by five years, according to Terran Biosciences CEO Sam Clark.
Psychedelic-assisted therapy offers hope, but faces FDA hurdles
Aaron Martin, a financial manager, found relief from depression and addiction through psychedelic treatments in Costa Rica, leading to significant lifestyle changes. The FDA's recent denial of MDMA for PTSD treatment highlights challenges in psychedelic therapy approval, though ongoing research at the University of Iowa explores psychedelics for alcoholism treatment. Experts emphasize the necessity of combining psychedelics with psychotherapy for effective mental health treatment.
Colorado researcher says people with PTSD are losing out on an effective treatment
A Boulder-based therapist is disappointed by the FDA's decision not to approve MDMA-assisted therapy for PTSD, despite a Phase III study showing 71% of participants no longer met PTSD criteria. The therapist argues the decision is a setback for PTSD sufferers, who often face severe symptoms and suicidal thoughts. The FDA's decision may be due to a lack of precedent for approving a therapy rather than just a drug.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath